Abstract | AIMS: METHOD: This retrospective study included 52 HBsAg-positive haemodialysis patients and 156 non-infected haemodialysis controls. Criteria adopted for starting lamivudine were the 2001 American Association for the Study of Liver Diseases guidelines. Lamivudine was commenced in 21 (40.4%) patients, with median treatment duration of 58 months. The primary endpoint was transplant-free survival. RESULTS: Survival of HBsAg-positive patients was equivalent to that of age- and sex-matched HBsAg-negative controls (39.1% vs 33.2% at 10 years, respectively; P=0.12). In treated patients, complete viral suppression was associated with improved survival (serial HBV DNA less than and equal to 2 log10 IU/mL, 90.9% vs HBV DNA >2 log10 IU/mL on at least one occasion, 74.1% at 5 years; P=0.049). Out of 20 deaths, three were liver-related. CONCLUSION: Haemodialysis patients with chronic HBV, when given oral antiviral therapy if indicated, had equivalent long-term survival to that of non-infected controls. In those with active viral hepatitis, viral suppression was associated with reduced liver-related mortality.
|
Authors | Maggie M G Ow, Janak R de Zoysa, Edward J Gane |
Journal | The New Zealand medical journal
(N Z Med J)
Vol. 127
Issue 1396
Pg. 34-42
(Jun 20 2014)
ISSN: 1175-8716 [Electronic] New Zealand |
PMID | 24997462
(Publication Type: Journal Article)
|
Chemical References |
- Hepatitis B Surface Antigens
- Reverse Transcriptase Inhibitors
- Lamivudine
|
Topics |
- Administration, Oral
- Aged
- Female
- Hepatitis B
(complications, drug therapy)
- Hepatitis B Surface Antigens
(blood)
- Humans
- Kaplan-Meier Estimate
- Kidney Failure, Chronic
(complications, therapy)
- Kidney Transplantation
- Lamivudine
(therapeutic use)
- Male
- Middle Aged
- Proportional Hazards Models
- Renal Dialysis
- Retrospective Studies
- Reverse Transcriptase Inhibitors
(therapeutic use)
- Survivors
|